CASI Key Statistics, Chart & Performance
The current stock price of CASI is 1.02 USD. In the past month the price increased by 20%. In the past year, price decreased by -58.79%.
CASI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CASI. When comparing the yearly performance of all stocks, CASI is a bad performer in the overall market: 93.08% of all stocks are doing better.
CASI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CASI. CASI may be in some trouble as it scores bad on both profitability and health.
CASI Financial Highlights
Over the last trailing twelve months CASI reported a non-GAAP Earnings per Share(EPS) of -2.02. The EPS increased by 40.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -150.05% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CASI Forecast & Estimates
7 analysts have analysed CASI and the average price target is 4.08 USD. This implies a price increase of 300% is expected in the next year compared to the current price of 1.02.
For the next year, analysts expect an EPS growth of -29.27% and a revenue growth -45.64% for CASI
CASI Ownership
About CASI
Company Profile
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The firm mainly conducts its business in the domestic market.
Company Info
CASI PHARMACEUTICALS INC
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District
Beijing BEIJING 20850 CN
CEO: Wei-Wu He
Employees: 233
Phone: 861065618789
CASI PHARMACEUTICALS INC / CASI FAQ
Can you describe the business of CASI PHARMACEUTICALS INC?
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The firm mainly conducts its business in the domestic market.
What is the stock price of CASI PHARMACEUTICALS INC today?
The current stock price of CASI is 1.02 USD. The price increased by 3.02% in the last trading session.
What is the dividend status of CASI PHARMACEUTICALS INC?
CASI does not pay a dividend.
What is the ChartMill technical and fundamental rating of CASI stock?
CASI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about CASI PHARMACEUTICALS INC (CASI) stock?
7 analysts have analysed CASI and the average price target is 4.08 USD. This implies a price increase of 300% is expected in the next year compared to the current price of 1.02.
What is the GICS sector and industry of CASI stock?
CASI PHARMACEUTICALS INC (CASI) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of CASI stock?
CASI PHARMACEUTICALS INC (CASI) has a market capitalization of 20.96M USD. This makes CASI a Nano Cap stock.